Share on LinkedInShare on LinkedIn

ARTICLE · 29 MARCH 2023

The State Of Biosimilars In 2023

It has been 13 years since the Biologics Price Competition and Innovation Act (BPCIA) was enacted and biosimilars had a pathway to enter the U.S. market.

United StatesIntellectual Property

INTRODUCTION

It has been 13 years since the Biologics Price Competition and Innovation Act (BPCIA) was enacted and biosimilars had a pathway to enter the U.S. market. While there have been challenges over this time, the U.S. biosimilar market has come a long way and has overcome many hurdles. We will explore some of the issues biosimilars have faced when entering the U.S. market, with a particular focus on the impact of inter partes reviews (IPRs), post grant reviews (PGRs), and the BPCIA litigation patent dance, as well as challenges to gaining market share after launch.

THE CURRENT STATE OF THE BIOSIMILARS INDUSTRY IN THE U.S.

There are currently1 40 approved biosimilars of 11 reference products in the U.S. market, seven of which were approved in 2022. This is a marked increase over the prior two years, which had seven total approvals due to COVID-19 related approval delays. Thus far, interchangeable approvals have been limited, with only four approved

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from